Reflections on Antiarrhythmic Agent Bepridil
نویسندگان
چکیده
منابع مشابه
Reflections on Agent Beliefs
Some issues concerning beliefs of agents are discussed. These issues are the general syntactic form of beliefs, the logic underlying beliefs, acquiring beliefs, and reasoning with beliefs. The logical setting is more expressive and aspects of the reasoning and acquisition processes are more general than are usually considered.
متن کاملElectrophysiological effects of the antiarrhythmic drug bepridil on the guinea-pig pulmonary vein myocardium.
We compared effects of the antiarrhythmic drug bepridil on the electrophysiological parameters in the isolated pulmonary vein preparation from guinea pigs with those in the left atrium. Three pairs of bipolar electrodes were attached to the left atrium, pulmonary vein and junctional region of left atrium and pulmonary vein to measure intra-atrial and intra-pulmonary vein conduction velocity and...
متن کاملUse of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
BACKGROUND It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR). The conversion effect of bepridil alone is not always satisfactory, however. The efficacy of pharmacological cardioversion by the combination of bepridil and a class Ic antiarrhythmic drug for persistent AF is studied. METHODS AND RESULTS The participa...
متن کاملBepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection.
Bepridil, which is clinically useful in the treatment of arrhythmias, has been reported to inhibit sarcolemmal ATP-sensitive K(+) (sarcK(ATP)) channels. However, the effect of bepridil on mitochondrial ATP-sensitive K(+) (mitoK(ATP)) channels remains unclear. The objective of the present study was to determine whether bepridil activates mitoK(ATP) channels and confers cardioprotection. SarcK(AT...
متن کاملPropafenone: a promising new antiarrhythmic agent.
(Chest 1990; 98:434-41) P ropafenone is a new class IC antiarrhythmic agent that has just l)een released in the United States for use in treatment o)f malignant ventricular arrhythmias (Rythmol, Knoll Pharmaceuticals, Whippany, New Jersey). It was first marketed in Europe in 1977, and has gained wide acceptance there and in Canada for the treatment of various types of ventricular and supraventr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Electrocardiology
سال: 2012
ISSN: 0285-1660,1884-2437
DOI: 10.5105/jse.32.51